ArticleRevista da Associacao Medica Brasileira (1992)2026
Preclinical safety and efficacy of "Yubivaks," a natural ointment for burn wounds: acute dermal toxicity and irritancy evaluation.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiotherapy: an emerging adjunct for burn wound healing.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNatural medicines are considered an effective strategy for treating burns. A preclinical study of a new natural ointment, "Yubivaks," was conducted to study acute dermal toxicity and irritant properties to ensure its safety.
methodsThe study investigated the acute dermal toxicity, local irritant effect on the skin and mucous membranes of eyes, and the sensitizing activity of the ointment. Adult nonlinear white rats and rabbits of both sexes were used in the experiment. The rats were randomly divided into three groups, each consisting of 10 animals: group I received recommended therapeutic dose (0.003 kg/day), group II received a "conditionally toxic" dose (0.020 kg /day), and group III served as the control group.
resultsThere were no deaths or signs of intoxication in the acute dermal toxicity study. No local irritant, resorptive, or sensitizing effect and positive immunological tests were observed at the therapeutic dose. Treatment of experimental burns with "Yubivaks" reduced the wound surface by half on the 7th day (59.6%); on the 15th day, the restoration of the histostructure of the epidermal tissue was 99.8%; and by the 25th day, the burn area was completely restored (100%) compared to "Levomekol": 43.6, 51.1, and 95.8%, respectively. Comparison with "Levomekol" was made based on its wide use as a recognized traditional medicine with complex action.
conclusionAt the recommended therapeutic dose, the ointment can be considered as an alternative medication due to accelerated regenerative processes, pronounced anti-inflammatory properties, and safety proven in experimental studies. A limitation of the study was that it was only conducted on rats and rabbits, without using guinea pigs or pig models for several reasons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.